To include your compound in the COVID-19 Resource Center, submit it here.

Lilly backs Topas' liver-specific nanoparticles platform

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Eli Lilly and Co. (NYSE:LLY) to develop therapeutics that induce antigen-specific immune tolerance. The companies

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE